Mission Statement, Vision, & Core Values (2024) of Neuronetics, Inc. (STIM)

Mission Statement, Vision, & Core Values (2024) of Neuronetics, Inc. (STIM)

US | Healthcare | Medical - Diagnostics & Research | NASDAQ

Neuronetics, Inc. (STIM) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Neuronetics, Inc. (STIM)

General Summary of Neuronetics, Inc. (STIM)

Neuronetics, Inc. is a commercial-stage medical technology company focused on developing and commercializing neuroscience treatments. The company's primary product is NeuroStar Advanced Therapy System for treating major depressive disorder.

Company Products and Services

  • NeuroStar TMS Therapy System
  • Mental health treatment technologies
  • Transcranial magnetic stimulation devices

Financial Performance Overview

Financial Metric 2023 Value
Total Revenue $159.4 million
Gross Profit $97.2 million
Net Loss $45.3 million

Market Position

Neuronetics holds a significant market share in transcranial magnetic stimulation (TMS) technology, with approximately 70% of the TMS therapy market in the United States.

Key Performance Indicators

Metric 2023 Data
NeuroStar Systems Installed 1,400+ healthcare facilities
Patient Treatments Over 1.5 million treatments delivered

Company Operational Highlights

  • Publicly traded on NASDAQ under ticker STIM
  • Headquartered in Malvern, Pennsylvania
  • Founded in 2002



Mission Statement of Neuronetics, Inc. (STIM)

Mission Statement of Neuronetics, Inc. (STIM)

Neuronetics, Inc. mission statement focuses on advancing mental health treatment through innovative neuromodulation technologies.

Core Components of Mission Statement

Component Specific Details Quantitative Metrics
Treatment Innovation NeuroStar Advanced Therapy TMS Platform FDA-cleared for Major Depressive Disorder in 2008
Clinical Effectiveness Non-invasive brain stimulation technology Over 4.4 million treatments performed as of 2023
Patient Access Expanding mental health treatment options Available in 1,500+ treatment centers nationwide

Key Technology Focus Areas

  • Transcranial Magnetic Stimulation (TMS)
  • Depression treatment solutions
  • Neurological disorder interventions

Financial Performance Indicators

Financial Metric 2023 Value
Total Revenue $159.4 million
R&D Expenditure $41.2 million
Market Capitalization Approximately $360 million

Clinical Impact Statistics

  • 65% patient response rate in depression treatment
  • 40% patient remission rate using NeuroStar technology
  • FDA-cleared for treatment-resistant depression

Neuronetics continues to prioritize technological advancement in mental health treatment through precision neuromodulation solutions.




Vision Statement of Neuronetics, Inc. (STIM)

Vision Statement of Neuronetics, Inc. (STIM) in 2024

Core Vision Framework

Neuronetics, Inc. focuses on advancing neuromodulation technologies for mental health treatment, specifically targeting treatment-resistant conditions.

Vision Dimension Specific Focus
Technological Innovation Advanced transcranial magnetic stimulation (TMS) platforms
Market Segment Psychiatric and neurological disorders treatment
Patient Reach Expanding access to non-invasive neurological treatments

Strategic Vision Components

Treatment Expansion Objectives
  • Develop next-generation TMS technologies
  • Expand clinical applications beyond depression
  • Improve patient outcomes through precision neurostimulation

Market Position and Growth Strategy

Neuronetics aims to maintain leadership in neuromodulation with NeuroStar TMS Therapy system, targeting:

Metric 2024 Target
Market Share Approximately 65% in TMS therapy market
Revenue Projection $75-85 million
Clinical Deployment Over 1,200 healthcare facilities

Research and Development Focus

Key R&D Priorities
  • Enhance NeuroStar Advanced Therapy platform
  • Explore new neurological disorder treatments
  • Improve treatment personalization algorithms



Core Values of Neuronetics, Inc. (STIM)

Core Values of Neuronetics, Inc. (STIM) in 2024

Patient-Centric Innovation

Neuronetics demonstrates commitment to patient-centric innovation through its TMS therapy platform. In 2023, the company reported 215,000 total patient treatments using NeuroStar Advanced Therapy.

Metric 2023 Performance
Total Patient Treatments 215,000
TMS Therapy Centers 1,400+
Scientific Integrity and Research Excellence

Neuronetics invests significantly in clinical research and development.

  • R&D Expenditure in 2023: $21.4 million
  • Clinical studies published: 7 peer-reviewed publications
  • FDA-cleared medical devices: 2 platforms
Operational Transparency

Financial transparency is demonstrated through detailed reporting.

Financial Metric 2023 Value
Total Revenue $159.3 million
Gross Margin 65.4%
Collaborative Healthcare Approach

Neuronetics partners with multiple healthcare networks and providers.

  • Healthcare Provider Partnerships: 250+
  • Mental Health Clinics Utilizing Technology: 1,100
Continuous Professional Development

Investment in employee training and development.

  • Annual Training Hours per Employee: 40
  • Employee Retention Rate: 87%

DCF model

Neuronetics, Inc. (STIM) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.